Brought to you by 
Two private equity firms buy Pfizer's diagnostic testing unit
27 Jan 2004
Executive Summary
Pfizer is selling its in vitro allergy and autoimmune diagnostic testing business to European private equity company Triton and PPM Ventures (Prudential's private equity arm) for $575mm in cash.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Two private equity firms buy Pfizer's diagnostic testing unit
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice